Entera Bio (NASDAQ:ENTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTXFree Report) in a research note released on Wednesday, Benzinga reports. They currently have a $10.00 price target on the stock.

Entera Bio Trading Down 0.5 %

Shares of Entera Bio stock opened at $2.09 on Wednesday. The firm’s 50-day moving average is $2.21 and its 200 day moving average is $1.39. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35.

Entera Bio (NASDAQ:ENTXGet Free Report) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Equities analysts expect that Entera Bio will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Virtu Financial LLC bought a new position in Entera Bio Ltd. (NASDAQ:ENTXFree Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is owned by institutional investors.

About Entera Bio

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.

Further Reading

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.